Immunogenic composition
AssigneeOxford University Innovation Limited
InventorsCraig THOMPSON, Sunetra GUPTA
Life of this patent
Estimating the term…
Abstract
The present invention relates to an immunogenic composition comprising two or more polypeptides. The invention also provides nucleic acid molecules and vectors encoding the polypeptides, and methods of using the compositions, nucleic acid molecules and vectors for the prevention or treatment of influenza.
Claims26
An immunogenic composition comprising at least five different virus-like particles (VLPs), wherein each VLP independently comprises one or more homotrimers comprised of polypeptides of SEQ ID NOs:
- 13-17, optionally together with one or more pharmaceutically-acceptable carriers, adjuvants, excipients or diluents, as a combined preparation in a form suitable for simultaneous, separate or sequential use for treating or preventing influenza A infection.
An immunogenic composition comprising two or more polypeptides, wherein each polypeptide independently comprises a first region of contiguous amino acids, wherein:
- (a) the amino acid sequence of the first region has at least 80% sequence identity to an influenza A haemagglutinin head domain;
- and
- (b) the first region has one or more amino acid substitutions at positions which correspond to the following positions in SEQ ID NO:
- 9:
- position 83 is E
- position 85 is a negatively charged amino acid
- position 146 is T, N, I or A
- position 147 is a positively charged amino acid, I or is absent
- position 148 is G
- position 149 is V
- position 151 is A
- position 154 is S or P
- position 155 is H
- position 156 is a positively charged amino acid or A or G or N or E
- position 157 is a positively charged amino acid or A or G
- position 158 is a positively charged amino acid or A or S or N or C or E
- position 159 is K or A or S or N or C
- position 163 is a positively charged amino acid,
- wherein the amino acid sequences of the two or more polypeptides are different, and
- wherein the composition is capable of inducing antibodies in a subject against an influenza A virus, optionally together with one or more pharmaceutically-acceptable carriers, adjuvants, excipients or diluents.
A composition comprising a polypeptide, wherein the amino acid sequence of the polypeptide comprises a first region, wherein:
- (a) the amino acid sequence of the first region has at least 80% sequence identity to an influenza A subtype H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17 or H18 haemagglutinin head domain, preferably an influenza A subtype H1, H5, H6, H9 or H11 haemagglutinin head domain;
- and
- (b) the first region has one or more amino acid substitutions at positions which correspond to the following positions in SEQ ID NO:
- 9:
- position 83 is E
- position 85 is a negatively charged amino acid
- position 146 is T, N, I or A
- position 147 is a positively charged amino acid, I or is absent
- position 148 is G
- position 149 is V
- position 151 is A
- position 154 is S or P
- position 155 is H
- position 156 is a positively charged amino acid or A or G or N or E
- position 157 is a positively charged amino acid or A or G
- position 158 is a positively charged amino acid or A or S or N or C or E
- position 159 is K or A or S or N or C
- position 163 is a positively charged amino acid.
17-19. (canceled)
22-25. (canceled)
27-32. (canceled)
34-43. (canceled)
Dependencies are inferred from the claim text.